Pioglitazone inhibits the amyloidogenic pathway, reducing BACE1, PSEN1, Aß42 levels and amyloid plaques [136–138], while increasing IDE and Pparg expression [136, 138] in PreDM and T2D models. Here, BACE1 is linked to amyloidosis.